Janus kinase inhibitors in dermatology: Part II. A comprehensive review

被引：26

作者：

Chapman, Stephanie ^{[1
]}

Gold, Linda Stein ^{[1
]}

Lim, Henry W. ^{[1
]}

机构：

[1] Henry Ford Hlth Syst, Dept Dermatol, 3031 W Grand Blvd,Suite 800, Detroit, MI 48202 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2022年 / 86卷 / 02期

关键词：

coronavirus; COVID-19; dermatology; immunology; immunodermatology; JAK inhibitor; Janus kinase inhibitor; Janus kinase-signal transducer and activator of transcription pathway; JAK-STAT pathway; review; ALOPECIA-AREATA; TOFACITINIB; VITILIGO; REPIGMENTATION; PATHOGENESIS; BARICITINIB; MECHANISMS;

D O I：

10.1016/j.jaad.2021.06.873

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The Janus kinase-signal transducer and activator of transcription (JAK-STAT) intracellular signaling pathway is implicated in the pathogenesis of a number of inflammatory dermatoses. Clinical trials and other studies have demonstrated the efficacy of JAK inhibitors in the treatment of a variety of dermatologic conditions. Here we review JAK inhibitors currently under investigation for the treatment of alopecia areata, vitiligo, sarcoidosis, necrobiosis lipoidica, granuloma annulare, and systemic lupus erythematosus with a special emphasis on safety and the implications of JAK inhibitors during the novel coronavirus 2019 pandemic. ( J Am Acad Dermatol 2022;86:414-22.)

引用

页码：414 / 422

页数：9

共 50 条

[31] Pharmacology of Janus kinase inhibitors
Solimani, F.
Hilke, F. J.
Ghoreschi, K.
HAUTARZT, 2019, 70 (12): : 934 - 941
[32] Thromboembolism and Janus Kinase Inhibitors
Fowzia Ibrahim
David L. Scott
Drug Safety, 2020, 43 : 831 - 833
[33] Investigational Janus kinase inhibitors
Tam, Constantine S.
Verstovsek, Srdan
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2013, 22 (06) : 687 - 699
[34] Itch and Janus Kinase Inhibitors
Han, Yujin
Woo, Yu Ri
Cho, Sang Hyun
Lee, Jeong Deuk
Kim, Hei Sung
ACTA DERMATO-VENEREOLOGICA, 2023, 103
[35] Thromboembolism and Janus Kinase Inhibitors
Ibrahim, Fowzia
Scott, David L.
DRUG SAFETY, 2020, 43 (09) : 831 - 833
[36] Ivermectin in small animal dermatology. Part II. Extralabel applications
Paradis, M
COMPENDIUM ON CONTINUING EDUCATION FOR THE PRACTICING VETERINARIAN, 1998, 20 (04): : 459 - +
[37] Janus-Kinase-HemmerJanus kinase inhibitors
E. Ostermeier
P. Roll
H.-P. Tony
Zeitschrift für Rheumatologie, 2012, 71 : 473 - 478
[38] Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology
Kostovic, Kresimir
Gulin, Sandra J.
Mokos, Zrinka B.
Ceovic, Romana
CURRENT MEDICINAL CHEMISTRY, 2017, 24 (11) : 1158 - 1167
[39] The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review
de Oliveira, Ana B.
Alpalhao, Miguel
Filipe, Paulo
Maia-Silva, Joao
DERMATOLOGIC THERAPY, 2019, 32 (05)
[40] A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
Tanaka, Yoshiya
INFLAMMATION AND REGENERATION, 2023, 43 (01)

← 1 2 3 4 5 →